GlassScriptPhysician profile
Nathan J Lohmeyer
NPI 1609950021
$2,665.38
in general payments reported to CMS, 2019-2025
20 companies · $291 in 2025
The $291 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $149 · 2020: $87.28 · 2021: $574 · 2022: $535 · 2023: $558 · 2024: $471 · 2025: $291.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,285 · Entertainment: $34.74.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,285.05 |
| Entertainment | $34.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $698.06 | 2019-2025 | Precision 1, Total30 |
| Bausch & Lomb Americas INC. | $365.21 | 2022-2025 | Infuse, Vyzulta, Miebo |
| Coopervision INC. | $301.03 | 2021-2025 | Misight Contact Lens, Myday Contact Lens |
| Johnson & Johnson Vision Care, INC. | $259.98 | 2020-2023 | Acuvue |
| Biotissue Holdings INC. | $203.81 | 2024 | |
| Allergan, INC. | $136.99 | 2021-2022 | |
| Carl Zeiss Meditec USA, INC. | $123.53 | 2022 | |
| Topcon Healthcare, INC. | $118.99 | 2023 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $84.50 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $63.68 | 2024-2025 | Xdemvy |
| Abb Con-Cise Optical Group LLC | $57.68 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $46.42 | 2024-2025 | |
| Horizon Therapeutics Plc | $40.36 | 2023 | Tepezza |
| Carl Zeiss Meditec Ag | $38.80 | 2020 | |
| Optos, INC. | $34.74 | 2023-2025 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $24.52 | 2023 | |
| Oyster Point Pharma, INC. | $22.60 | 2023 | Tyrvaya |
| Lombart Brothers, INC. | $15.46 | 2025 | Opd-III |
| Sight Sciences, INC. | $14.61 | 2022 | |
| Novartis Pharmaceuticals Corporation | $14.41 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Lohmeyer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.